Comparative Pharmacology
Head-to-head clinical analysis: HYDELTRA TBA versus MAGNACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDELTRA TBA versus MAGNACORT.
HYDELTRA-TBA vs MAGNACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, modulating gene transcription to suppress inflammation, immune response, and adrenal function.
Corticosteroid receptor agonist; modulates gene transcription to produce anti-inflammatory and immunosuppressive effects.
20-40 mg intramuscularly every 3 weeks; for intra-articular use: 20-40 mg per large joint, 10-20 mg per medium joint, 4-10 mg per small joint.
5 mg orally once daily for 7 days, then 5 mg orally every other day for 7 days. Alternatively, 1 mg/kg intravenously every 12 hours for 14 days.
None Documented
None Documented
Plasma t1/2 ~2.5-3.5 hours. Duration of adrenal suppression may persist for 24-48 hours.
3.5 ± 0.8 hours (terminal); prolonged in renal impairment (up to 12 hours in ESRD) and hepatic disease; requires dose adjustment in CrCl <30 mL/min
Primarily renal (80-90% as inactive metabolites and unchanged drug). Biliary excretion accounts for <5%.
Renal (80% as unchanged drug and metabolites, primarily via glomerular filtration and tubular secretion); biliary/fecal (15%)
Category C
Category C
Corticosteroid
Corticosteroid